公开(公告)号：US11098071B2

公开(公告)日：2021-08-24

申请号：US16490837

申请日：2018-02-28

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun Nan ,  Xin Xie ,  Linhai Chen ,  Qing Zhang ,  Yufeng Xiao ,  Hui Yang

IPC: C07F9/09 ,  C07F9/655 ,  C07F9/6553 ,  C07F9/6561

Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.

公开(公告)号：US10105362B2

公开(公告)日：2018-10-23

申请号：US14916463

申请日：2014-05-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Qiang Yu ,  Jing He ,  Qing Zhang

IPC: A61K31/5025 ,  C12N5/09

Abstract: The present invention provides an anti-tumor use of Anagrelide and derivatives thereof and, more specifically, the present invention provides the use of Anagrelide and derivatives thereof in the preparation of pharmaceuticals or pharmaceutical compositions for the treatment or inhibition of tumors.